Urothelial cancers: using biology to improve outcomes

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer40(3), 1246–1268 (1977).
   PubMed Web of Science ®Google Scholar
• Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control8(3), 444–472 (1997).
   PubMed Web of Science ®Google Scholar
• Elsebai I. Parasites in the etiology of cancer – bilharziasis and bladder cancer. CA Cancer J. Clin.27(2), 100–106 (1977).
   PubMedGoogle Scholar
• Murta-Nascimento C, Silverman DT, Kogevinas M et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol. Biomarkers Prev.16(8), 1595–1600 (2007).
   PubMed Web of Science ®Google Scholar
• Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J. Urol.166(6), 2129–2133 (2001).
   PubMed Web of Science ®Google Scholar
• MacVicar AD. Bladder cancer staging. BJU Int.86(Suppl. 1), 111–122 (2000).
   PubMedGoogle Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature414(6859), 105–111 (2001).
   PubMed Web of Science ®Google Scholar
• Jordan CT, Guzman ML, Noble M. Cancer stem cells. N. Engl. J. Med.355(12), 1253–1261 (2006).
   PubMed Web of Science ®Google Scholar
• Gedye C, Davidson AJ, Elmes MR, Cebon J, Bolton D, Davis ID. Cancer stem cells in urologic cancers. Urol. Oncol.28(6), 585–590 (2010).
   PubMedGoogle Scholar
• van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum. Mol. Genet.9(20), 2973–2980 (2000).
   PubMed Web of Science ®Google Scholar
• Simon R, Eltze E, Schafer KL et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res.61(1), 355–362 (2001).
   PubMed Web of Science ®Google Scholar
• Jones TD, Wang M, Eble JN et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin. Cancer Res.11(18), 6512–6519 (2005).
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Noninvasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol. Int.60(1), 1–8 (2010).
   PubMedGoogle Scholar
• Greene FL. TNM: our language of cancer. CA Cancer J. Clin.54(3), 129–130 (2004).
   PubMedGoogle Scholar
• DeVita VH, Rosenberg SA. Cancer: Principles and Practice of Oncology Lippincott Williams & Williams, PA, USA (2005).
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465; discussion 475–467 (2006).
   PubMed Web of Science ®Google Scholar
• Miyao N, Tsai YC, Lerner SP et al. Role of chromosome 9 in human bladder cancer. Cancer Res.53(17), 4066–4070 (1993).
   PubMed Web of Science ®Google Scholar
• Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene18(16), 2657–2661 (1999).
   PubMed Web of Science ®Google Scholar
• Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Rev. Anticancer Ther.8(7), 1103–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Lindgren D, Frigyesi A, Gudjonsson S et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res.70(9), 3463–3472 (2010).
   PubMed Web of Science ®Google Scholar
• Karni-Schmidt O, Castillo-Martin M, HuaiShen T et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol.178(3), 1350–1360 (2011).
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol.6(9), 678–686 (2005).
   PubMed Web of Science ®Google Scholar
• George B, Datar RH, Wu L et al.p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J. Clin. Oncol.25(34), 5352–5358 (2007).
   PubMed Web of Science ®Google Scholar
• Stadler WM, Lerner SP, Groshen S et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ-confined node-negative urothelial bladder cancer (UBC). J. Clin. Oncol.27(Suppl. 15), (2009) (Abstract 5017).
   Google Scholar
• Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J. Urol.164(5), 1523–1525 (2000).
   PubMed Web of Science ®Google Scholar
• Roupret M, Zigeuner R, Palou J et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur. Urol.59(4), 584–594 (2011).
   PubMed Web of Science ®Google Scholar
• Roupret M, Catto J, Coulet F et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J. Med. Genet.41(7), e91 (2004).
   Google Scholar
• Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol. Oncol.29(2), 130–136 (2011).
   PubMed Web of Science ®Google Scholar
• Oku S, Higashi M, Imazono Y et al. Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract. BJU Int.91(1), 109–114 (2003).
   PubMedGoogle Scholar
• Nakanishi K, Ogata S, Hiroi S, Tominaga S, Aida S, Kawai T. Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract. Am. J. Clin. Pathol.130(1), 43–49 (2008).
   PubMed Web of Science ®Google Scholar
• Catto JW, Azzouzi AR, Rehman I et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol.23(13), 2903–2910 (2005).
   PubMed Web of Science ®Google Scholar
• van Oers JM, Zwarthoff EC, Rehman I et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur. Urol.55(3), 650–657 (2009).
   PubMed Web of Science ®Google Scholar
• Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res.14(5), 1291–1295 (2008).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Paz-Ares L, Cuello M et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol.18(3), 522–528 (2007).
   PubMed Web of Science ®Google Scholar
• Font A, Taron M, Gago JL et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann. Oncol.22(1), 139–144 (2011).
   PubMed Web of Science ®Google Scholar
• Gallagher D, Joseph V, Garcia-Grossman IR et al. Germline single-nucleotide polymorphisms (SNPs) associated with response of urothelial carcinoma (UC) to platinum-based therapy: the role of the host. J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract 236).
   PubMedGoogle Scholar
• Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette–Guerin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol.6(9), 1450–1455 (1988).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171(6 Pt 1), 2186–2190; quiz 2435 (2004).
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette–Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol.13(6), 1404–1408 (1995).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168(5), 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol.59(6), 997–1008 (2011).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Orsola A, Maldonado X, Kataja V. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v134–v136 (2010).
   Google Scholar
• Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int. J. Radiat. Oncol. Biol. Phys.30(2), 261–266 (1994).
   PubMed Web of Science ®Google Scholar
• Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol.20(14), 3061–3071 (2002).
   PubMed Web of Science ®Google Scholar
• Konety BR, Joslyn SA, O’Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J. Urol.169(3), 946–950 (2003).
   PubMed Web of Science ®Google Scholar
• Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J. Urol.177(2), 437–443 (2007).
   PubMed Web of Science ®Google Scholar
• Elzayat EA, Al-Zahrani AA. Pelvic lymphadenectomy in the treatment of invasive bladder cancer: literature review. Adv. Urol.701481 (2011).
   PubMedGoogle Scholar
• Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J. Clin. Oncol.23(10), 2358–2365 (2005).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet361(9373), 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol.171(2 Pt 1), 561–569 (2004).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48(2), 202–205; discussion 205–206 (2005).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst. Rev.2, CD005246 (2005).
   PubMedGoogle Scholar
• David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol.178(2), 451–454 (2007).
   PubMed Web of Science ®Google Scholar
• Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol.19(20), 4005–4013 (2001).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349(9), 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol.29(16), 2171–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Hall MC, Swanson DA, Dinney CP. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology47(6), 826–830 (1996).
   PubMedGoogle Scholar
• Scher HI, Yagoda A, Herr HW et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J. Urol.139(3), 470–474 (1988).
   PubMed Web of Science ®Google Scholar
• Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer115(5), 988–996 (2009).
   PubMed Web of Science ®Google Scholar
• Dash A, Pettus JAt, Herr HW et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer113(9), 2471–2477 (2008).
   PubMed Web of Science ®Google Scholar
• Weight CJ, Garcia JA, Hansel DE et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer115(4), 792–799 (2009).
   PubMedGoogle Scholar
• Ghadjar P, Burkhard FC, Gautschi O, Thalmann GN, Studer UE. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int.107(6), 894–897 (2011).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer ‘unfit’ for cisplatin-based chemotherapy. J. Clin. Oncol.29(17), 2432–2438 (2011).
   PubMed Web of Science ®Google Scholar
• Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol.54(1), 126–132 (2008).
   PubMed Web of Science ®Google Scholar
• Vale CL, Advanced Bladder Cancer Meta-analysis collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst. Rev.2, CD006018 (2006).
   Google Scholar
• Loehrer PJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.10(7), 1066–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: erratum. J. Clin. Oncol.11(2), 384 (1993).
   PubMedGoogle Scholar
• Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.15(7), 2564–2569 (1997).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J. Clin. Oncol.19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer42(1), 50–54 (2006).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, von der Maase H, Mead GM et al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J. Clin. Oncol.25(18S), (2007) (Abstract LBA5030).
   PubMedGoogle Scholar
• Boukovinas I, Androulakis N, Vamvakas L et al. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter Phase II study of the Hellenic Oncology Research Group. Ann. Oncol.17(11), 1687–1692 (2006).
   PubMedGoogle Scholar
• Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol11(9), 861–870 (2010).
   PubMed Web of Science ®Google Scholar
• Culine S, Theodore C, De Santis M et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer94(10), 1395–1401 (2006).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
   PubMed Web of Science ®Google Scholar
• Witte RS, Elson P, Bono B et al. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol.15(2), 589–593 (1997).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Canil CM, Mukherjee SD et al. Results of a Phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC). J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract 241).
   Google Scholar
• Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer34(8), 1208–1212 (1998).
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Hartlein M et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma – prognostic factors for response and improvement of quality of life. Onkologie25(1), 47–52 (2002).
   PubMedGoogle Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol.24(21), 3451–3457 (2006).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest. New Drugs25(3), 265–270 (2007).
   PubMed Web of Science ®Google Scholar
• Albers P, Park SI, Niegisch G et al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol.22(2), 288–294 (2011).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr. et al. Results of the Southwest Oncology Group Phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int.105(3), 317–321 (2010).
   PubMed Web of Science ®Google Scholar
• Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A Phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann. Oncol.20(6), 1074–1079 (2009).
   PubMed Web of Science ®Google Scholar
• Jin Y, Iwata KK, Belldegrun A et al. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol. Cancer Ther.5(7), 1754–1763 (2006).
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Nielsen M, Heathcote S et al. A Phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int.106(3), 349–354 (2010).
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res.6(12), 4874–4884 (2000).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology66(6 Suppl. 1), 64–74 (2005).
   PubMed Web of Science ®Google Scholar
• Jimenez RE, Hussain M, Bianco FJ Jr. et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res.7(8), 2440–2447 (2001).
   PubMed Web of Science ®Google Scholar
• Kruger S, Weitsch G, Buttner H et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int. J. Cancer102(5), 514–518 (2002).
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol.25(16), 2218–2224 (2007).
   PubMed Web of Science ®Google Scholar
• Beuzeboc P, Banu E, Voog E et al. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized Phase II study. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I.25(18S), (2007) (Abstract 15565).
   Google Scholar
• Wulfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer115(13), 2881–2890 (2009).
   PubMed Web of Science ®Google Scholar
• Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl Cancer Inst.87(21), 1603–1612 (1995).
   PubMed Web of Science ®Google Scholar
• Papadopoulos I, Giatromanolaki A, Koukourakis MI, Sivridis E. Tumour angiogenic activity and vascular survival ability in bladder carcinoma. J. Clin. Pathol.57(3), 250–255 (2004).
   PubMedGoogle Scholar
• Hahn NM, Stadler WM, Zon RT et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75. J. Clin. Oncol.29(12), 1525–1530 (2011).
   PubMed Web of Science ®Google Scholar
• Twardowski P, Stadler WM, Frankel P et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology76(4), 923–926 (2010).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol. Oncol.27(4), 391–399 (2009).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol.28(8), 1373–1379 (2010).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer115(18), 4090–4095 (2009).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Winquist E, Eisen A et al. A Phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest. New Drugs29(5), 1045–1049 (2010).
   PubMedGoogle Scholar
• Krege S, Rexer H, vom Dorp F, Albers P, De Geeter P, Klotz T. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). J. Clin. Oncol.28(15s), (2010) (Abstract 4574).
   Google Scholar
• Necchi A, Nicolai N, Ortega C et al. Updated results of INT70/09 Phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC). J. Clin. Oncol.29 (2011) (Abstract 4618).
   Google Scholar
• Choueiri TK, Vaishampayan UN, Yu EY et al. A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer. J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract LBA239).
   Google Scholar
• Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest.116(7), 1935–1945 (2006).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer110(12), 2614–2627 (2007).
   PubMed Web of Science ®Google Scholar
• Carthon BC, Wolchok JD, Yuan J et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res.16(10), 2861–2871 (2010).
   PubMed Web of Science ®Google Scholar
• Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol.3(11), 1463–1470 (1985).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol.18(5), 1058–1061 (2000).
   PubMed Web of Science ®Google Scholar
• Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol.22(2), 220–228 (2004).
   PubMed Web of Science ®Google Scholar